Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection

Exclusion Criteria

• •Liver transplant recipients
• •Documented or suspected hepatocellular carcinoma
• •Evidence of decompensated cirrhosis
• •History of chronic hepatitis B virus (HBV). Patients with resolved HBV infection may participate
• •Current or known history of cancer
• •Any gastrointestinal disease or surgical procedure that may impact the absorption of study drug
• •Inability to tolerate oral medication
• •Poor venous access
• •Severe psychiatric disease
• •History of chronic pulmonary disease
• •History of cardiomyopathy, coronary artery disease (including angina), interventive procedure for coronary artery disease (including angioplasty, stent procedure, or cardiac bypass surgery), ventricular arrhythmia,, or other clinically significant cardiac disease
• •History of or current electrocardiogram findings indicative of cardiovascular instability
• •Preexisting ophthalmologic disorders considered clinically significant on eye
• •History of uncontrolled diabetes mellitus
• •Any known contraindication to pegylated interferon alfa-2a or ribavirin not otherwise specified.
• •Positive hepatitis B virus surface antigen, HIV-1 or HIV-2 Ab
• •Prior exposure to any HCV direct antiviral agent (eg, HCV protease, polymerase, previous nonstructural protein 5A inhibitors)
• •Exposure to any investigational drug or placebo